Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortPD-L1 checkpoint inhibitor given by infusion.Immunotherapy for many cancers — the world's top-selling medicine.
Body systemCancerCancer
Drug classImmune checkpoint inhibitorsImmune checkpoint inhibitors
SupplyPrescription onlyPrescription onlyWHO essential medicine
Main usesNon-small-cell and small-cell lung cancer, Urothelial (bladder) cancer, Liver cancer (with bevacizumab)Melanoma, Non-small cell lung cancer, Kidney, bladder, head and neck cancers, Triple-negative breast cancer, Cervical and endometrial cancer
How it worksHelps the immune system attack cancer.Takes the brakes off your immune cells so they can find and kill cancer.
Starts workingDepends on the cancer and regimen—
Half-lifeAbout 27 daysAbout 22 days
Typical adult doseDosed by your cancer team according to the treatment protocol.200 mg every 3 weeks or 400 mg every 6 weeks IV.
FormsIV infusionIV infusion, Subcutaneous injection
Common side effectsTiredness, Rash, Nausea, Cough, Loss of appetiteTiredness, Rash and itch, Diarrhoea, Underactive thyroid
Serious side effectsImmune-related colitis, hepatitis, pneumonitis, thyroid and adrenal problems, Infusion reactionsPneumonitis, Colitis, Hepatitis, Type 1 diabetes, Myocarditis, Adrenal or pituitary failure
Don't take ifActive serious autoimmune disease (caution); Pregnancy—
AlcoholUsually no problem in moderation. No specific interaction.—
PregnancyUsually avoidedCan harm a developing baby. Effective contraception is advised during and after treatment.Usually avoidedContraception needed.
BreastfeedingUsually avoidedAvoid breastfeeding during treatment.—
In use since—2014
Brand namesUnited States: TecentriqUnited Kingdom: TecentriqIndia: TecentriqUnited States: Keytruda, Keytruda QlexUnited Kingdom: KeytrudaIndia: Keytruda
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H—
ATC codeL01FF05L01FF02

Taken together

No interaction between these medicines is recorded in the atlas.

Open in the interaction checker